Trials / Unknown
UnknownNCT01048151
TNFerade Biologic to Treat Locally Advanced Prostate Cancer
A PHASE I SAFETY AND TOLERABILITY TRIAL OF RADIOTHERAPY, ANDROGEN DEPRIVATION, AND INTRATUMORAL INJECTIONS OF AdGVEGR.TNF.11D (TNFeradeTM) FOR PATIENTS WITH LOCALLY ADVANCED PROSTATE CANCER
- Status
- Unknown
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- Sponsor
- GenVec · Industry
- Sex
- Male
- Age
- —
- Healthy volunteers
- Not accepted
Summary
While radiation therapy with androgen ablation (hormone reduction) is the standard method of treating locally advanced prostate cancer. New treatments are being combined with radiation therapy in an effort to further improve the cure rates. This study proposes to combine an experimental drug, TNFerade™ Biologic, (also called AdGVEGR.TNF.11D or "TNFerade") at different dose (amounts) levels in combination with radiation. TNFerade™ Biologic is a form of gene transfer therapy that when injected into the tumor has shown to increase the effect of radiation therapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | TNFerade™ Biologic | AdGVEGR.TNF.11D |
Timeline
- First posted
- 2010-01-13
- Last updated
- 2012-03-12
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01048151. Inclusion in this directory is not an endorsement.